NFJ Investment Group LLC Makes New $1.60 Million Investment in Omnicell, Inc. (NASDAQ:OMCL)

NFJ Investment Group LLC acquired a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 35,897 shares of the company's stock, valued at approximately $1,598,000. NFJ Investment Group LLC owned 0.08% of Omnicell as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its position in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock worth $35,000 after buying an additional 273 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after purchasing an additional 315 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Omnicell during the 4th quarter valued at $53,000. First Horizon Advisors Inc. lifted its stake in shares of Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the last quarter. Finally, Huntington National Bank boosted its holdings in Omnicell by 236.4% in the fourth quarter. Huntington National Bank now owns 1,359 shares of the company's stock worth $61,000 after purchasing an additional 955 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on OMCL. Benchmark restated a "buy" rating and set a $62.00 target price on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com raised Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday, April 15th. Wells Fargo & Company decreased their target price on Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Finally, Bank of America decreased their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $50.67.

Omnicell Stock Performance

Omnicell stock traded up $0.81 during mid-day trading on Wednesday, reaching $30.73. The company had a trading volume of 150,556 shares, compared to its average volume of 533,389. The company has a 50 day moving average of $34.85 and a 200-day moving average of $41.10. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of 113.82, a PEG ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, sell-side analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.